Cataract News and Research

Latest Cataract News and Research

Emergency room visits increase in Mass., plus more hospital news

The Boston Globe: In Massachusetts, "[t]he number of people visiting hospital emergency rooms has climbed … despite the enactment of nearly universal health insurance that some hoped would reduce expensive emergency department use. According to state data released last week, emergency room visits rose by 9 percent from 2004 to 2008, to about 3 million visits a year.

7 Jul 2010

Alcon signs definitive agreement to acquire LenSx Lasers

Alcon, Inc. announced today that it has entered into a definitive agreement to acquire LenSx Lasers, Inc, a privately held company that developed the first femtosecond laser to receive U.S. Food and Drug Administration clearance for use as a part of cataract surgery. The LenSx system is indicated for anterior capsulotomy and laser phacofragmentation during cataract surgery, providing a complementary surgical approach to certain manual steps within the traditional cataract procedure.

7 Jul 2010

Research findings suggest new treatment approach to improve corneal transplants

Although it is already one of medicine's most successful transplant procedures, doctors continue to seek ways to improve corneal transplants. Now, for the first time, a team of German and British researchers have confirmed that failure and rejection of transplanted corneas are more likely in patients whose eyes exhibit abnormal vessel growth, called corneal neovascularization, prior to surgery.

1 Jul 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.

23 Jun 2010

STAAR Surgical on list of preliminary additions to Russell 3000, Microcap, Global indexes

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it has been included on a list of preliminary additions to the Russell 3000® Index, the Russell Microcap® Index and the Russell Global® Index posted by Russell Investments on June 11, 2010 on www.russell.com.

14 Jun 2010

Latinos have highest rates of eye disease: New research

New research suggests Latinos have the highest rates of eye disease in the United States, and one Los Angeles area clinic, Eye Physicians of Long Beach, is supremely prepared to meet the community's eye care needs.

2 Jun 2010

Congress needs to replace current outdated Medicare payment system

The Alliance of Specialty Medicine, representing over 100,000 specialty physicians nationwide, released the following statement on Congress's unwillingness to improve and permanently fix the Medicare reimbursement system:

29 May 2010

Amgen announces European approval of Prolia

Amgen Inc. today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

28 May 2010

STAAR Surgical to retire 1.7 million preferred shares through cash payment to Canon companies of $6.8M

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that it will retire 1.7 million preferred shares through a cash payment to the Canon companies of $6.8 million. STAAR originally issued the 1.7 million Series A Convertible Preferred shares as part of the Company's December 2007 purchase of the remaining 50% interest in Canon Staar Co., Inc.

21 May 2010

STAAR Surgical receives CE Mark approval for product improvements to Visian Implantable Collamer Lens

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced CE Mark approval for a range of product improvements to the Company's Visian Implantable Collamer® Lens (ICL™) that more than doubles the current Visian addressable market in Europe.

20 May 2010

FDA grants LensAR Laser System 510(k) clearance for use in anterior capsulotomy during cataract surgery

LensAR, Inc., the leading developer of next generation laser technology for cataract surgery and presbyopia, today announced that the company has received 510(k) clearance from the FDA for use of the LensAR Laser System for anterior capsulotomy during cataract surgery.

18 May 2010

Phakic IOLs safer than laser surgery for correcting moderate short-sightedness

A new type of procedure for correcting short-sightedness could be safer than laser eye surgery, according to a new Cochrane Systematic Review. The study also shows that patients prefer the new procedure, despite there being little difference between the two in terms of improving vision.

12 May 2010

HOYA reports 26.4% increase in fourth-quarter 2010 net sales

HOYA Corporation today announced financial results for the fourth quarter and fiscal year ended March 31, 2010. Net sales were 104.8 billion yen for the quarter, representing an increase of 26.4% from 82.9 billion yen in the same period last year, mainly due to a recovery in orders in the main business fields such as Electro-Optics, as well as the cost-reduction achieved through structural reform.

7 May 2010

Caffeine is effective in preventing cataract formation, says study

Caffeine may be effective in protecting the lens against damage that could lead to the formation of cataracts, according to a study presented on May 4 at the 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology.

6 May 2010

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome™ Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale, Florida.

5 May 2010

Landec announces acquisition of Lifecore Biomedical from Warburg Pincus Private Equity

Landec Corporation, a materials science company that develops and markets patented polymer products for food, agriculture, personal care and drug delivery applications, today announced that it has acquired Lifecore Biomedical, Inc. from Warburg Pincus Private Equity IX, LP. When acquired by Warburg Pincus in March 2008, Lifecore was comprised of two divisions, the Dental Division and the Hyaluronan Division. The Dental Division was merged into a Warburg Pincus portfolio company.

3 May 2010

ISTA Pharmaceuticals first-quarter net revenues up 39%

ISTA Pharmaceuticals, Inc., today reported financial results for the quarter ended March 31, 2010. First quarter 2010 net revenues were $28.3 million, an increase of 39% from the first quarter of 2009. Net income for the first quarter ended March 31, 2010, was $0.5 million, or $0.01 per share, compared to a net loss of $19.6 million, or $0.59 per share, for the first quarter ended March 31, 2009.

30 Apr 2010

DRCR Network study finds new treatment more effective

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration.

28 Apr 2010

Cataract News and Research

Latest Cataract News and Research

Emergency room visits increase in Mass., plus more hospital news

Alcon signs definitive agreement to acquire LenSx Lasers

Research findings suggest new treatment approach to improve corneal transplants

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

STAAR Surgical on list of preliminary additions to Russell 3000, Microcap, Global indexes

Latinos have highest rates of eye disease: New research

Congress needs to replace current outdated Medicare payment system

Amgen announces European approval of Prolia

STAAR Surgical to retire 1.7 million preferred shares through cash payment to Canon companies of $6.8M

STAAR Surgical receives CE Mark approval for product improvements to Visian Implantable Collamer Lens

FDA grants LensAR Laser System 510(k) clearance for use in anterior capsulotomy during cataract surgery

Phakic IOLs safer than laser surgery for correcting moderate short-sightedness

HOYA reports 26.4% increase in fourth-quarter 2010 net sales

Caffeine is effective in preventing cataract formation, says study

IBI to present data on Verisome Liquid Drug Delivery System for cystoid macular edema at ARVO 2010

Landec announces acquisition of Lifecore Biomedical from Warburg Pincus Private Equity

ISTA Pharmaceuticals first-quarter net revenues up 39%

DRCR Network study finds new treatment more effective

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cataract News and Research

Latest Cataract News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in